Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

SIMPLE SUMMARY: Medication adherence to CDK4/6 inhibitors such as palbociclib, prescribed as a cyclic oral anticancer therapy in women diagnosed with advanced breast cancer, may be suboptimal. We evaluated adherence to palbociclib and its impact on pharmacokinetic and pharmacodynamic (PK-PD) profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandiera, Carole, Locatelli, Isabella, Courlet, Perrine, Cardoso, Evelina, Zaman, Khalil, Stravodimou, Athina, Dolcan, Ana, Sarivalasis, Apostolos, Zurcher, Jean-Philippe, Aedo-Lopez, Veronica, Dotta-Celio, Jennifer, Peters, Solange, Guidi, Monia, Wagner, Anna Dorothea, Csajka, Chantal, Schneider, Marie P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818079/
https://www.ncbi.nlm.nih.gov/pubmed/36612312
http://dx.doi.org/10.3390/cancers15010316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818079/
https://www.ncbi.nlm.nih.gov/pubmed/36612312
http://dx.doi.org/10.3390/cancers15010316

Ejemplares similares